Seres Therapeutics Inc., of Cambridge, Mass., commenced an underwritten registered public offering of $60 million of shares of its common stock. Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9 million of shares. Goldman Sachs & Co. LLC and Cowen and Co. LLC are acting as joint book-running managers.